We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MZTF:TASEMizrahi Tefahot Bank Ltd Analysis

Data as of 2026-03-14 - not real-time

ILA 23,050.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Mizrahi Tefahot Bank trades around 23,050 ILA, comfortably below its 20‑day (≈24,277) and 50‑day (≈24,363) moving averages, with an RSI of ~40 and a bearish MACD histogram, indicating short‑term momentum pressure despite an overall neutral trend and rising volume. Fundamentally, the stock appears deeply undervalued – its trailing P/E of ~10.9 is well under the industry average of 16.3, and the discounted cash‑flow model suggests a fair value near 81,708 ILA, implying upside of over 13% from current levels. The bank delivers a solid 4.48% dividend yield with a payout ratio around 42%, supporting the case for dividend sustainability. Recent news shows Q4 profit fell more than expected, but the bank maintains strong operating margins (≈62%) and a healthy ROE (~17%).
Given the low beta (~0.1) and modest market‑cap risk, the equity presents a compelling value play with attractive income, though regulatory and sector‑specific headwinds temper enthusiasm. Investors should weigh the short‑term technical weakness against the long‑term valuation gap and robust dividend profile when shaping their position.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages
  • Bearish MACD signal
  • Rising volume indicating potential accumulation

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF upside of ~13% and P/E discount to peers
  • Strong dividend yield and sustainable payout
  • Low beta and improving earnings quality

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Consistent high operating margins and ROE
  • Undervalued valuation metrics relative to industry
  • Stable regulatory environment for major Israeli banks

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin39.21%
P/E Ratio10.9
ROE16.94%
ROA1.13%
P/B Ratio172.4
Op. Cash FlowILA15.8B
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI40.3
SupportILA 22,610.00
ResistanceILA 25,920.00
MA 20ILA 24,277.50
MA 50ILA 24,363.00
MA 200ILA 21,727.55
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair ValueILA 81,708.31
Target PriceILA 26,081.25
Upside/Downside13.15%
GradeUndervalued
TypeValue
Dividend Yield4.48%

Risk Assessment

Beta0.10
Volatility31.99%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.